Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2009-05-21
- Lead Sponsor
- Bradmer Pharmaceuticals Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00906516
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
Phase 3
Terminated
- Conditions
- Glioblastoma Multiforme
- Interventions
- Drug: Radiation Therapy + Temozolomide
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2011-02-10
- Lead Sponsor
- Bradmer Pharmaceuticals Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT00615186
News
No news found